Effect of the association of 1-methyl-DL-tryptophan with paclitaxel on the expression of indoleamine 2,3-dioxygenase in cultured cancer cells from patients with breast cancer

详细信息    查看全文

• 作者：Maria Letícia Baptista Salvadori ; Pedro Kastein Faria da Cunha Bianchi…
• 关键词：Cancer ; associated therapy ; Flow cytometry ; IDO ; In vitro treatment ; Taxol? ; Tryptophan catabolism
• 刊名：Medical Oncology
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：32
• 期：11
• 全文大小：341 KB
• 参考文献：1.American cancer society. 2014. http://?www.?cancer.?org/?cancer/?breastcancer/?index . Accessed on 15 May 2014.
  2.Barksdale AR, Bernard AC, Maley ME, Gellin GL, Kearney PA, Boulanger BR, Tsuei BJ, Ochoa JB. Regulation of arginase expression by T-helper II cytokines and isoproterenol. Surgery. 2004. doi:10.-016/-003.-0.-07 .PubMed
  3.Bekki K, Vogel H, Li W, Ito T, Sweeney C, Haarmann-Stemmann T, Matsumura F, Vogel CF. The aryl hydrocarbon receptor (AhR) mediates resistance to apoptosis induced in breast cancer cells. Pestic Biochem Physiol. 2015. doi:10.-016/?j.?pestbp .PubMed
  4.Boasso A, Herbeuval JP, Hardy AW, Winkler C, Shearer GM. Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells. Blood. 2005. doi:10.-182/-004-06-2089 .PubMed Central
  5.Bronte V, Serafini PS, Marigo I, Tosello V, Mazzoni A, Segal DM, Lowel M, Sutter G, Colombo MP, Zanovello P. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol. 2003. doi:10.-049/-70.-.-70 .
  6.Hou DY, Muller AJ, Sharma MD, Duhadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 2007. doi:10.-158/-008-5472 .
  7.Kohler BA, Ward E, Mccarthy BJ, Schymura MJ, Ries LAG, Eheman C, Jemal A, Anderson RN, Ajani UA, Edwards BK. Annual report to the nation on the status of cancer, featuring tumors of the brain and other nervous system. J Natl Cancer Inst. 2011. doi:10.-093/?jnci/?djr077 .PubMed Central PubMed
  8.Munn DH, Mellor LA. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013. doi:10.-016/?j.?it.-012.-0.-01 .PubMed Central PubMed
  9.Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL. Expression of IDO by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Investig. 2004. doi:10.-172/?JCI200421583 .PubMed
  10.Munn DH. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol. 2006. doi:10.-016/-006.-1.-02 .PubMed
  11.Ng VG, Mena C, Pietras C, Lansky AJ. Local delivery of paclitaxel in the treatment of peripheral arterial disease. Eur J Clin Investig. 2015. doi:10.-111/?eci.-2407 .
  12.Platten M, Wick W, Optiz C. Immune modulation by tryptophan metabolism: relevance for autoimmune and tumor diseases. Dtsch Med Wochenschr. 2013. doi:10.-055/?s-0033-1343222 .PubMed
  13.Potula R, Poluektova L, Knipe B, Chrastil J, Heilman D, Dou H, Takikawa O, Munn DH, Gendelman HE, Persidsky Y. Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in animal model of HIV-1 encephalitis. Blood. 2005. doi:10.-182/-005-04-1403 .PubMed Central
  14.Ruel-Gariépy E, Shive M, Bichara A, Berrada M, Le Garrec D, Chenite A, Leroux JC. A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel. Eur J Pharm Biopharm. 2004. doi:10.-016/?S0939-6411(03)00095-X .
  15.Schmidt SK, Siepmann S, Kuhlmann K, Meyer HE, Metzger S, Pudelko S, Leineweber M, D?ubener W. Influence of tryptophan contained in 1-Methyl-Tryptophan on antimicrobial and immunoregulatory functions of indoleamine 2,3-dioxygenase. PLoS One. 2012. doi:10.-371/?journal.?pone.-044797 .
  16.Ueda S, Satoh T, Gotoh M, Gao L, Doi T. A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas. Oncologist. 2015. doi:10.-634/-014-0440 .PubMed Central PubMed
  17.Wang Y, Yang BH, Li H, Cao S, Ren XB, Yu JP. IDO(+) DCs and signalling pathways. Curr Cancer Drug Targets. 2013. doi:10.-174/-568009611313999-073 .PubMed Central
  18.Ying W, Wang S, Shi J, Sun Y. ER-/ER?+?breast cancer cell lines exhibited different resistance to paclitaxel through pulse selection. Med Oncol. 2011. doi:10.-007/?s12032-011-9889-9 .
  
• 作者单位：Maria Letícia Baptista Salvadori (1)
  Pedro Kastein Faria da Cunha Bianchi (1)
  Luiz Henrique Gebrim (2)
  Renata Santos Silva (1)
  José Roberto Kfoury Jr (1)
  
  1. Anatomy Section, Department of Surgery, School of Veterinary Medicine and Animal Sciences, University of S?o Paulo, Av. Prof. Dr. Orlando Marques Paiva 87, Butant?, S?o Paulo, SP, 05508-270, Brazil
  2. Department of Tocogynecology, Federal University of Sao Paulo, Rua Botucatu, 740. Vila Clementino, S?o Paulo, SP, 04023900, Brazil
  
• 刊物主题：Oncology; Hematology; Pathology; Internal Medicine;
• 出版者：Springer US
• ISSN：1559-131X

文摘

Breast cancer is the most common type of cancer among women and the survival of patients affected by it is increasing, mainly due to several new approaches in early diagnosis and more effective treatments. The enzyme indoleamine 2,3-dioxygenase (IDO) is expressed in many cells, including tumor cells. IDO acts by inhibiting the proliferation of T lymphocytes, thus compromising their cytotoxic activity. 1-Methyl-DL-tryptophan (1MT) is a competitive inhibitor of IDO, which blocks its immunosuppressive effect. Paclitaxel is an antineoplastic drug largely used in breast cancer therapy. Thus, this study aimed to determine the in vitro effect of the association of 1MT and paclitaxel chemotherapy, as an approach to reduce tumor growth. It is believed that this would allow the restoration of T lymphocyte proliferation capability and its cytotoxic response. The supplemented cultures showed that the most significant differences in the expression of IDO were observed in the group treated with paclitaxel associated with 1-MT continuous supplementation, reducing enzyme expression from 12.06 to 3.56 %. This association was more effective in reducing IDO expression and could collaborate in developing a new therapeutic strategy for breast cancer treatment. Keywords Cancer-associated therapy Flow cytometry IDO In vitro treatment Taxol? Tryptophan catabolism